CATALYST PHARMACEUTICALS INC (CPRX) Stock News

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (

Why NASDAQ:CPRX qualifies as a high growth stock.

Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

First Week of CPRX September 19th Options Trading

Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.

Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase.

Unlocking the high Growth Potential of NASDAQ:CPRX.

Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s high Growth Prospects.

BeiGene Stock Meets 80-Plus RS Rating Benchmark

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

NASDAQ:CPRX, an undervalued stock with good fundamentals.

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

BridgeBio Pharma Stock Earns 87 RS Rating

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

One of Catalyst's key products has protection against a knockoff from Teva until 2035.

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035...

Interesting CPRX Call Options For January 17th

Arcellx Stock Earns 82 Relative Strength Rating

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution...

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (

BioNTech Stock Got A IBD RS Rating Lift

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (